Last reviewed · How we verify
Seasonal trivalent influenza vaccine, VAXIGRIP
Seasonal trivalent influenza vaccine, VAXIGRIP is a Biologic drug developed by Center for Disease Prevention and Control of Beijing Military Region. It is currently FDA-approved. Also known as: VAXIGRIP.
VAXIGRIP is a marketed seasonal trivalent influenza vaccine developed by the Center for Disease Prevention and Control of Beijing Military Region. The key composition patent for VAXIGRIP is set to expire in 2028, providing a period of exclusivity that supports its market position. The primary risk is the potential increase in competition following the patent expiry, which could impact revenue and market share.
At a glance
| Generic name | Seasonal trivalent influenza vaccine, VAXIGRIP |
|---|---|
| Also known as | VAXIGRIP |
| Sponsor | Center for Disease Prevention and Control of Beijing Military Region |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vaccine (PHASE4)
- Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults (PHASE4)
- Immune Response of Intradermal and Intramuscular Preparations of Inactive Seasonal Influenza Vaccine in Older Age Group. (PHASE4)
- Safety and Immunogenicity of Three Seasonal Trivalent Influenza Vaccines in China Military (PHASE4)
- Comparison of 4 Influenza Vaccines in Seniors (PHASE4)
- Immunogenicity and Safety of Different Dosing Schedules of Trivalent Influenza Vaccine in HIV-infected Pregnant Women (PHASE3)
- Differences in Response to the Flu Vaccine Among Adults With HIV and Without HIV in Uganda (NA)
- Immunogenicity and Safety Trial of Adjuvanted and Non-adjuvanted Trivalent Influenza Vaccine in Tropical Africa (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Seasonal trivalent influenza vaccine, VAXIGRIP CI brief — competitive landscape report
- Seasonal trivalent influenza vaccine, VAXIGRIP updates RSS · CI watch RSS
- Center for Disease Prevention and Control of Beijing Military Region portfolio CI
Frequently asked questions about Seasonal trivalent influenza vaccine, VAXIGRIP
What is Seasonal trivalent influenza vaccine, VAXIGRIP?
Who makes Seasonal trivalent influenza vaccine, VAXIGRIP?
Is Seasonal trivalent influenza vaccine, VAXIGRIP also known as anything else?
What development phase is Seasonal trivalent influenza vaccine, VAXIGRIP in?
Related
- Manufacturer: Center for Disease Prevention and Control of Beijing Military Region — full pipeline
- Also known as: VAXIGRIP
- Compare: Seasonal trivalent influenza vaccine, VAXIGRIP vs similar drugs
- Pricing: Seasonal trivalent influenza vaccine, VAXIGRIP cost, discount & access